Digoxin/furosemide - Cutanea Life Sciences
Alternative Names: CLS-003; Furosemide/digoxin; ICVT; Ionic contra viral therapyLatest Information Update: 07 Sep 2021
At a glance
- Originator Henderson Morley
- Developer Cutanea Life Sciences; Henderson Morley
- Class Antihypertensives; Antivirals; Glycosides; Skin disorder therapies; Small molecules; Sulfanilamides
- Mechanism of Action Loop diuretics; Potassium channel antagonists; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Actinic keratosis; Genital warts; Herpes simplex virus infections; Human papillomavirus infections; Infectious keratoconjunctivitis; Vulvar intraepithelial neoplasia; Warts
Most Recent Events
- 07 Sep 2021 Discontinued - Phase-II for Actinic keratosis (In the elderly, In adults) in Netherlands (Topical) before September 2021 (Cutanea Life Sciences' website, September 2021)
- 07 Sep 2021 Discontinued - Phase-II for Genital warts in Netherlands (Topical) before September 2021 (Cutanea Life Sciences' website, September 2021)
- 07 Sep 2021 Discontinued - Phase-II for Vulvar intraepithelial neoplasia in Netherlands (Topical) before September 2021 (Cutanea Life Sciences' website, September 2021)